Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema
Akihiro Ohira, Katsunori Hara, Gauti Jóhannesson, Masaki Tanito, Gudrún Marta Ásgrímsdóttir, Sigrún H Lund, Thorsteinn Loftsson, Einar Stefánsson, Akihiro Ohira, Katsunori Hara, Gauti Jóhannesson, Masaki Tanito, Gudrún Marta Ásgrímsdóttir, Sigrún H Lund, Thorsteinn Loftsson, Einar Stefánsson
Abstract
Purpose: To compare in a randomized, controlled trial topical 1.5% dexamethasone γ-cyclodextrin nanoparticle eye drops (DexNP) with posterior subtenon injection of triamcinolone acetonide in diabetic macular oedema (DME).
Methods: In this prospective, randomized, controlled trial, 22 eyes of 22 consecutive patients with DME were randomized to (i) topical treatment with DexNP ×3/day (4 weeks), ×2/day (4 weeks) and ×1/day (4 weeks) or (ii) one posterior subtenon injection of 20 mg triamcinolone acetonide. Study visits were at baseline and 4, 8, 12 and 16 weeks.
Results: The logMAR (Snellen) visual acuity (mean ± SD) improved significantly with DexNP from 0.41 ± 0.3 (Snellen 0.39) to 0.32 ± 0.25 (0.48) and 0.30 ± 0.26 (0.50) at 4 and 8 weeks, respectively. One-third of the DexNP group improved more than 0.3 logMAR units. For triamcinolone, logMAR changed significantly from 0.42 ± 0.28 (0.38) at baseline to 0.32 ± 0.29 (0.48) at 4w and 0.33 ± 0.37 (0.47) at 12w. The central macular thickness (CMT) decreased significantly with DexNP from 483 ± 141 μm to 384 ± 142 μm at 4w and 342 ± 114 μm at 8w. For triamcinolone, CMT decreased significantly at all time-points: 494 ± 94 μm, 388 ± 120, 388 ± 145, 390 ± 136 and 411 ± 104 μm at 0, 4, 8, 12 and 16 weeks, respectively. There was a modest increase in intraocular pressure (IOP) at all time-points with DexNP while no increase was seen with triamcinolone. Serum cortisol was affected by both treatments.
Conclusion: Topical DexNP significantly improve visual acuity and decrease macular thickness in patients with DME. The effect is similar to that from subtenon triamcinolone. A modest increase in IOP was seen with the nanoparticle eye drops, but IOP normalized after the discontinuation of treatment.
Keywords: cyclodextrin; dexamethasone; diabetes macular edema; nanoparticle; topical treatment; triamcinolone.
© 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Source: PubMed
다가오는 임상 시험
-
University Medical Center Groningen모병Myalgic Encephalomyelitis / Chronic Fatigue Syndrome네덜란드
-
University of Malaya아직 모집하지 않음
-
University of ReginaNational Football League모병
-
National Heart, Lung, and Blood Institute (NHLBI)아직 모집하지 않음
-
National Cancer Institute (NCI)아직 모집하지 않음신생물 | 대장 신생물 | 간내 담관암종 | 부신피질 암종 | 전이, 신생물미국
-
Yunlong Wang아직 모집하지 않음
-
Maastricht University Medical CenterWinclove Probiotics B.V.모병건강한 | 여성 | 성인 | 남성 | 과체중(BMI > 25) | 포만감과 음식 섭취 | 장내 미생물 총 변조 | 과체중, 비만네덜란드
-
Erasmus Medical CenterHealth∼Holland, Topsector Life Sciences & Health; Politecnico di Milano University; Spatium...모병
-
Shanghai Mental Health Center아직 모집하지 않음추체외로 증상 | 지발성 운동이상증(TD) | 정좌불능증, 약물 유발 | 약물 유발 파킨슨증중국